Replies to post #142446 on Biotech Values

[NP1986]

The description on clinicaltrials.gov only specifies that the patient must have failed standard therapies, but AFAIK that would typically include an oxaliplatin-based regimen followed by an irinotecan-based regimen, or vice versa.